BioSpace News Archive

New research in the April 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography use by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference.

Drug delivery devices is used to inject a drug to the body through a specific direction with more accuracy, ease, and less frequent dosing. There are various types of drug delivery devices, some of which include drug eluting stents, smart pills, safety syringes, inhalers, and more.

A vascular graft is a surgical procedure that reconnects blood vessels and redirects blood flow from one part of the body to another. They are widely used for the surgery of vascular diseases.

Upon completion of the Additional ADSL Purchase, Britannia will own a 70% interest in ADSL, Britannia’s largest operating subsidiary.

CytoImmune Therapeutics announced that Christina Coughlin, M.D., Ph.D., chief executive officer, will participate in the following April investor conferences.

Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Canaccord Genuity Horizons in Oncology Virtual Conference being held on Thursday, April 14, 2022 at 10:00 a.m. ET.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2022 results before the market opens on Tuesday, May 3, 2022, to be followed by a conference call at 8:30 a.m. (Eastern Time).

R1 RCM Inc. (NASDAQ:RCM), today announced that Project Roadrunner Parent Inc., a wholly owned subsidiary of R1, has publicly filed a registration statement on Form S-4 relating to its previously announced proposed acquisition of Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a secondary analysis of a Phase 2 clinical trial of MN-166 (ibudilast) in alcohol use disorder (AUD) was published in the journal Alcoholism: Clinical and Experimental Research.